Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Figures corrected NBB
Corrected annual account filed for 2023.
Financials
Financial year 2025
CANCER STATE THERAPEUTICS from Charleroi, company number BE0793113273, closed financial year 2025 with a result of € -690,490 after tax. For that financial year CANCER STATE THERAPEUTICS recorded a gross margin of € -105,252 and equity of € 3.7 million. Compared with financial year 2024, the result moved from € -451,570 to € -690,490. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 15, 2026.
€ 3.7 million
▲ € 3.3 million vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -690,490
▼ 53 % more loss than in 2024
Profit after tax over the fiscal year.
€ 171,917
▼ 53% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -1.5 million.
People and assets in 2025
€ 593,089
▲ 120% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 28,185
▼ 73% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 55,491
▲ 62% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|
| Gross margin | € -186,642 | € -114,896 | € -105,252 | ▲ € 9,645 |
| Profit after taxes | € -330,453 | € -451,570 | € -690,490 | ▼ € 238,920 |
| Equity | € 880,722 | € 429,152 | € 3,738,662 | ▲ € 3.3 million |
| Total debts | € 467,165 | € 170,937 | € 222,178 | ▲ 30% |
| Cash | € 760,439 | € 365,382 | € 171,917 | ▼ 53% |
| Retained profit | € -330,453 | € -782,023 | € -1,472,513 | ▼ € 690,490 |
| Balance sheet total | € 1,347,887 | € 600,089 | € 3,960,840 | ▲ € 3.4 million |
Key figures of CANCER STATE THERAPEUTICS, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to CANCER STATE THERAPEUTICS?
What happened at CANCER STATE THERAPEUTICS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 690,490. Source: NBB ↗
- Pierre Chevalier became a director. NBB
- François Delvaux became a director. NBB
- New establishment in Charleroi. KBO
- Start of the company according to the CBE. KBO
In short
From € 330,453 loss in 2023 to € 690,490 loss in 2025.
A new publication or filing at CANCER STATE THERAPEUTICS? We notify you, reason included.
Follow CANCER STATE THERAPEUTICSDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind CANCER STATE THERAPEUTICS are Ahmed Fahim, Gaetan Waucquez, Pierre Chevalier, Jean-Claude Marian, Cédric Blanpain and François Delvaux. Gaetan Waucquez is also behind ARLON 32. Pierre Chevalier is also behind Cristallerie du Val Saint Lambert, GEORGE FORREST EUROPE, VOSSENSTEERT and GROUPE FORREST INTERNATIONAL.
Directors
According to the 2025 annual accounts
Ahmed Fahim
Director
Pierre Chevalier
Director
Also active at: Cristallerie du Val Saint Lambert, GEORGE FORREST EUROPE, VOSSENSTEERT, GROUPE FORREST INTERNATIONAL
since 2025
Jean-Claude Marian
Director
Cédric Blanpain
Managing director
François Delvaux
Director
since 2025
Establishments
Establishment units
Physical locations of this company
Rue Auguste Piccard 48
6041 Charleroi
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.
All companies at this address →SYNABS
€ 742,551 gross margin · 2025
European Infrared Technologies
€ 53,354 gross margin · 2024
HEARTKINETICS
€ -463,720 gross margin · 2022
Genflow Biosciences
€ -264,246 gross margin · 2025
NEUVASQ BIOTECHNOLOGIES
€ 641,586 gross margin · 2025
+1 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0793.113.273
- VAT number
- BE 0793.113.273
- Registered office
- Rue Auguste Piccard 48, 6041 Charleroi
- Names & denominations
- CANCER STATE THERAPEUTICS
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 28 October 2022
- Peppol
- Active · Active since 9 Nov 2022
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied